XSpray Financial Statements From 2010 to 2024

XSPRAY Stock  SEK 71.80  1.20  1.64%   
XSpray Pharma financial statements provide useful quarterly and yearly information to potential XSpray Pharma AB investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on XSpray Pharma financial statements helps investors assess XSpray Pharma's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting XSpray Pharma's valuation are summarized below:
XSpray Pharma AB does not presently have any fundamental gauges for analysis.
Check XSpray Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among XSpray Pharma's main balance sheet or income statement drivers, such as , as well as many indicators such as . XSpray financial statements analysis is a perfect complement when working with XSpray Pharma Valuation or Volatility modules.
  
This module can also supplement various XSpray Pharma Technical models . Check out the analysis of XSpray Pharma Correlation against competitors.

XSpray Pharma AB Company Shares Owned By Insiders Analysis

XSpray Pharma's Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.

Insiders Shares

 = 

Executives Shares

+

Employees

More About Shares Owned By Insiders | All Equity Analysis

Current XSpray Pharma Shares Owned By Insiders

    
  47.42 %  
Most of XSpray Pharma's fundamental indicators, such as Shares Owned By Insiders, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, XSpray Pharma AB is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.
Competition

Based on the latest financial disclosure, 47.42% of XSpray Pharma AB are shares owned by insiders. This is 212.38% higher than that of the Healthcare sector and 234.41% higher than that of the Biotechnology industry. The shares owned by insiders for all Sweden stocks is notably lower than that of the firm.

XSpray Pharma AB Fundamental Drivers Relationships

Comparative valuation techniques use various fundamental indicators to help in determining XSpray Pharma's current stock value. Our valuation model uses many indicators to compare XSpray Pharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across XSpray Pharma competition to find correlations between indicators driving XSpray Pharma's intrinsic value. More Info.
XSpray Pharma AB is rated second in return on equity category among its peers. It is rated second in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value XSpray Pharma by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for XSpray Pharma's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.

About XSpray Pharma Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include XSpray Pharma income statement, its balance sheet, and the statement of cash flows. XSpray Pharma investors use historical funamental indicators, such as XSpray Pharma's revenue or net income, to determine how well the company is positioned to perform in the future. Although XSpray Pharma investors may use each financial statement separately, they are all related. The changes in XSpray Pharma's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on XSpray Pharma's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on XSpray Pharma Financial Statements. Understanding these patterns can help to make the right decision on long term investment in XSpray Pharma. Please read more on our technical analysis and fundamental analysis pages.
Xspray Pharma AB engages in developing protein kinase inhibitors for targeted cancer treatments in Sweden. Xspray Pharma AB was founded in 2003 and is based in Solna, Sweden. Xspray Pharma is traded on Stockholm Stock Exchange in Sweden.

Pair Trading with XSpray Pharma

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if XSpray Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in XSpray Pharma will appreciate offsetting losses from the drop in the long position's value.

Moving together with XSpray Stock

  0.66BIOA-B BioArctic ABPairCorr
  0.81CAMX Camurus ABPairCorr
  0.94HNSA Hansa Biopharma ABPairCorr

Moving against XSpray Stock

  0.67ALM ALM Equity ABPairCorr
  0.62NANOFS Nanoform Finland PlcPairCorr
The ability to find closely correlated positions to XSpray Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace XSpray Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back XSpray Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling XSpray Pharma AB to buy it.
The correlation of XSpray Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as XSpray Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if XSpray Pharma AB moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for XSpray Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Other Information on Investing in XSpray Stock

XSpray Pharma financial ratios help investors to determine whether XSpray Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in XSpray with respect to the benefits of owning XSpray Pharma security.